Data from a 22-patient study that assessed the safety and efficacy of sofosbuvir/velpatasvir/voxilaprevir over a 12-week period in patients with hepatitis B, hepatitis C genotype 3 and HIV showed that the direct-acting antiviral manifested an 87% sustained virologic response rate. Details were presented at the ACG Annual Scientific Meeting.
Drug combo effective in treating triple-infected cohort, study finds
Sign up for ACG SmartBrief
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.